MediWound's EscharEx Shows Safe, Effective, Rapid Debridement Of Leg Ulcers

Comments
Loading...
  • MediWound Ltd MDWD announced results from its Phase 2 pharmacology study of EscharEx for the debridement of lower leg ulcers.
  • 70% of patients achieved complete debridement during treatment within up to 8 applications. On average, complete debridement was achieved after 3.9 applications of EscharEx. 
  • Additionally, an average reduction of 35% in wound size was achieved by the end of the 2-week follow-up period. 
  • Related: MediWound Posts Promising EscharEx Data For Chronic Wounds.
  • In all patients that were positive for biofilm at baseline, the biofilm was reduced substantially to single individual microorganisms or entirely removed by the end of treatment. 
  • Seven patients had positive red fluorescence (indicative of bacteria) at baseline, and the average red fluorescence was reduced from 1.69 cm2 pre-treatment to 0.60 cm2 post-treatment. 
  • Biomarker analysis from wound fluid is ongoing, and safety data shows EscharEx is safe and well-tolerated.
  • Price Action: MDWD shares are up 1.10% at $1.83 during the premarket session on the last check Thursday.
Market News and Data brought to you by Benzinga APIs

Posted In:
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!